● Recruiting

Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy

Condition: Breast Cancer · Sponsor: Peking University Cancer Hospital & Institute

PhaseNA

Planned participants50

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with ADC therapy

This description comes directly from the study's public registry record.

Talk to the study team

Xiaoyi Guo, PhD · 010-88196495 · 15833916752@163.com

Yannan Yuan · 01088197730 · gcp_yuanyn@bjcancer.org

Always discuss trial participation with your own doctor first.

Locations (1)

Peking University Cancer Hospital & Institute

Beijing, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06909604